Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A primary or metastatic malignant neoplasm affecting the pituitary gland. Representative examples include functioning or non-functioning carcinomas arising from the anterior lobe of the pituitary gland, chordomas, chondrosarcomas, and metastatic carcinomas from the breast, lung, and gastrointestinal tract.
Biomarker and diagnostic research for pituitary cancer has been reported in the published literature.
3 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
135 publications have been identified in PubMed for pituitary cancer. Research spans Review / Meta-Analysis (54%), Basic Science / Preclinical (13%), and Case Report / Case Series (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 73 | 54% |
Data assembled from 3 of 12 sources · Last updated Oct 4, 2026, 3:02 AM UTC
Laboratory research | 18 | 13% |
Patient case studies | 13 | 10% |
Clinical study results | 12 | 9% |
Disease patterns and progression | 11 | 8% |
Other research | 4 | 3% |
Testing and diagnosis research | 3 | 2% |
New treatment approaches | 1 | 1% |
Castle-Kirszbaum M (2026). [PMID: 41781297](https://pubmed.ncbi.nlm.nih.gov/41781297/). *Best Pract Res Clin Endocrinol Metab*. [Review / Meta-Analysis]
Nagaoka T (2026). [PMID: 41940233](https://pubmed.ncbi.nlm.nih.gov/41940233/). *JCEM Case Rep*. [Case Report / Case Series]
Raventos A (2026). [PMID: 41498150](https://pubmed.ncbi.nlm.nih.gov/41498150/). *Pol Arch Intern Med*. [Review / Meta-Analysis]
Caballero GA (2026). [PMID: 41912298](https://pubmed.ncbi.nlm.nih.gov/41912298/). *Vitam Horm*. [Review / Meta-Analysis]
Lotfian G (2026). [PMID: 40773058](https://pubmed.ncbi.nlm.nih.gov/40773058/). *Neuroradiology*. [Case Report / Case Series]
McIntyre MK (2026). [PMID: 41718148](https://pubmed.ncbi.nlm.nih.gov/41718148/). *NeuroSci*. [Review / Meta-Analysis]
Losa M (2026). [PMID: 41493525](https://pubmed.ncbi.nlm.nih.gov/41493525/). *J Endocrinol Invest*. [Epidemiology / Natural History]
Faraj CA (2026). [PMID: 42250176](https://pubmed.ncbi.nlm.nih.gov/42250176/). *J Neurooncol*. [Review / Meta-Analysis]
Papalou O (2026). [PMID: 41850963](https://pubmed.ncbi.nlm.nih.gov/41850963/). *Best Pract Res Clin Endocrinol Metab*. [Review / Meta-Analysis]
Glezer A (2026). [PMID: 41234156](https://pubmed.ncbi.nlm.nih.gov/41234156/). *J Clin Endocrinol Metab*. [Review / Meta-Analysis]